Episode 4 (January 12, 2024): Takeaways from the J.P. Morgan Health Care conference: Illumina, Danaher, 10x, Empress Therapeutics; an interview with Liberate Bio’s Shawn Davis and Walter Strapps. 

Listed below are references to relevant GEN stories discussed in this episode of Touching Base: 

• JPM: Illumina’s new CEO spells out 2024 priorities, presents preliminary Q4 2023 results 

By Alex Philippidis, GEN, January 10, 2024. 

• JPM: Prime Medicine eyes 2024 IND for first prime editing therapy 

By Alex Philippidis, GEN, January 9, 2024 

• JPM 2024: Veracyte’s C2i genomics acquisition adds AI readouts to liquid biopsy testing 

By Jonathan D. Grinstein, GEN, January 8, 2024 

• JPM: More M&A “firepower” in store for 2024, EY predicts 

By Alex Philippidis, GEN, January 8, 2024 

Hosted on Acast. See acast.com/privacy for more information.